EarningsQ3 2026 Earnings Report
MX:COR Q3 2026 EPS Results
Actual EPS$76.26
Consensus EPS$74.00
Beat/MissBeat by +$2.26
One Year Ago EPS$68.09
MX:COR Q3 2026 Revenue Results
Actual Revenue$1.44T
Expected Revenue$1.44T
Beat/MissBeat by +$7.49B
YoY Revenue Growth+5.07%
Earnings Announcement Details
QuarterQ3 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
MX:COR Upcoming Earnings
Cencora's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:COR Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong execution and durable specialty-driven growth: consolidated revenue and adjusted gross profit growth, margin expansion, double-digit operating income increases, 12% EPS growth, upgraded EPS guidance, significant share repurchases, and robust free cash flow. Key drivers included strong U.S. Healthcare Solutions performance (MSOs and specialty), International momentum, and OneOncology outperforming expectations. Headwinds discussed were notable but largely manageable: $2.4B of manufacturer list-price reductions, a prior oncology customer loss, lower mail-order sales, acquisition-related higher operating expenses and increased interest expense, and a potential FY27 earnings headwind from the planned MWI transaction. Overall, the positive operational and financial outcomes and guidance raise outweigh the discrete and partly acquisition-related challenges.Company Guidance
Consolidated Revenue Growth
Consolidated revenue of $84.8B, up 5% year-over-year, driven by growth across reportable segments and Other.
Strong Gross Profit and Margin Expansion
Consolidated adjusted gross profit of $3.5B, up 23% YoY, with gross profit margin expanding 61 basis points to 4.16%, aided by the OneOncology acquisition.
Operating Income and EPS Growth
Consolidated adjusted operating income was $1.2B, up 17% YoY; delivered 12% adjusted EPS growth in the quarter and raised full-year adjusted EPS guidance to $17.75–$17.95 (from $17.70–$17.90).
U.S. Healthcare Solutions Outperformance
U.S. Healthcare Solutions revenue $74.9B, up 5% YoY; segment operating income $966M, up 16% YoY, with double-digit organic operating income growth excluding the OneOncology contribution and prior-year customer loss.
International Segment Momentum
International Healthcare Solutions revenue $7.7B, up 6% YoY (as-reported and constant currency), and operating income $166M, up 21% as-reported (23% constant currency), driven by European distribution, World Courier and European 3PL.
Specialty and GLP-1 Strength
Specialty trends drove growth across MSOs, health systems and physician practices; GLP-1 sales increased ~$2.3B YoY (approximately +25%), contributing meaningfully to U.S. revenue growth.
Capital Returns and Balance Sheet Actions
Completed $1B of opportunistic share repurchases in the quarter at an average of $268/share (diluted shares down ~0.7% to 193.9M); ended June with $2.8B cash, YTD adjusted free cash flow $1.1B, and maintained full-year adjusted FCF guidance of ~ $3B. Also repaid $800M of RCA financing-related term loan ($400M in quarter and $400M in July).
MSO Execution and OneOncology Performance
MSO platforms (OneOncology and RCA) performed ahead of expectations; OneOncology is modestly better than initial expectations and expected to be neutral to adjusted EPS over a 12-month period net of financing.
Raised Operating Income Guidance
Raised bottom end of consolidated operating income growth guidance to 13%–14%; U.S. Healthcare Solutions operating income growth guidance now 14.5%–15.5%; International operating income growth ~9%; Other operating income growth ~10%.
MX:COR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed